As part of our mission to eliminate cancer, Torrance Memorial Hunt Cancer Institute physicians conduct several clinical trials to test new treatments for both common and rare cancers. Look through our clinical trials list to find studies for which you may be eligible.
Hunt Cancer Institute Active Clinical Trials
These studies are currently enrolling participants.
| Disease | Title | Summary | Status | Investigator |
| Breast Cancer | RAVEL RB-AG-PLT-01 "EMBRACE" | Evaluation of Novel Blood-Based Biomarkers for Detection of Breast Cancer (EMBRACE) | Open/Active | Swati Sikaria, MD |
| GI- COLORECTAL CANCER (CRC) | NATERA "BESPOKE" 20-041-NCP | BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer | Open/Active | Syed Jilani, MD |
| SOLID TUMOR: BREAST, STAGE 1 COLON, ALL LIVER CANCER | LAM "ELITE" 001-2018 | Collection of Blood from Healthy Patients, Patients with Benign Disease and Patients with Cancer | Open/Active | David Chan, MD |
| COLON, LUNG - NON SMALL CELL LUNG CANCER, MELANOMA | NATERA 20-043-NCP "BESPOKE IO" | BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO) | Open/Active | Syed Jilani, MD |
| SOLID TUMOR | EXACT SCIENCES THR-CS-001 "DETECT-ASCEND 2" | Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) | Open/Active | David Chan, MD |
Active Trials - UCLA Trials
The following clinical trials are available at Torrance Memorial Physician Network Cancer Care and are in coordination with the TRIO-US / Clinical Trials Network.
| Disease | Title | Summary | Status | Investigator | |
| BREAST | TRIO 033 ‐ Novartis CLEE011O12301C "NATALEE" | Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]:NATALEE) | Open/Active | David Chan, MD | |
| BREAST | NSABP B-59 / GBG 96-GeparDouze TNBC | A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo. | Open/Active | David Chan, MD | |
| BREAST | Seattle Genetics SGNTUC-016 "HER2 CLIMB-02" | Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer. | Open/Active | David Chan, MD | |
| BREAST | TRIO-038 - Roche WO42133 | A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE II, NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH POSTMENOPAUSAL WOMEN. ANASTROZOLE PLUS PALBOCICLIB FOR POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE UNTREATED EARLY BREAST CANCER | Open/Active | David Chan, MD | |
| BREAST | TRIO-US B-12 (TALENT) | A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of trastuzumab deruxtecan (DS-8201a) with or without anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting | Open/Active | David Chan, MD | |
| PANCREATIC | Ipsen "NAPOLI-3" | An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil / leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas. | Open/Active | Hugo Hool, MD | |
| LUNG - NON SMALL CELL LUNG CANCER | Mirati 516-005 "SAPPHIRE" | A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy. | Open/Active | Thomas Lowe, MD | |
| CHRONIC LYMPHOCYTIC LEUKEMIA | Acerta ACE-CL-311 (D8221C00001) CLL | A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation. | Open/Active | Swati Sikaria, MD | |
| TRIPLE NEGATIVE BREAST CANCER (TNBC) | NOVARTIS CBYL719H12301-EPIK-B3 | EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation. | Open/Active |
|
Cedars-Sinai Trials
| Disease | Title | Summary | Status | Investigator |
| BRAIN- GLIOBLASTOMA (GBM) | NCI NRG-BN007 | A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA | Open/Active | Andrew Horodner, MD & Jeremy Rudnick, MD |
| BRAIN METASTASES | NCI ALLIANCE A071701 | GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES | Open/Active | Andrew Horodner, MD & Jeremy Rudnick, MD |
| BREAST-DCIS | AFT-25 "COMET" | COMPARISON OF OPERATIVE TO MONITORING AND ENDOCRINE THERAPY (COMET) TRIAL FOR LOW RISK DCIS: A PHASE III PROSPECTIVE RANDOMIZED TRIAL, https://dcisoptions.org/ | Open/Active | Swati Sikaria, MD & Armando Giuliano, MD |
| BREAST | NCI ALLIANCE A011401 "BWEL" | RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER | Open/Active | Swati Sikaria, MD & Arash Asher, MD |
| BREAST | IIT2018-04-MCARTHUR-NEOHIP "NeoHIP" | Neoadjuvant HER2-targeted Therapy and Immunotherapy with Pembrolizumab (neoHIP) | Open/Active | Swati Sikaria, MD & Heather McArthur, MD |
| GI- COLORECTAL CANCER (CRC) | NCI ALLIANCE A021703 "SOLARIS" | RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS) | Open/Active | Syed Jilani, MD & Jun Gong, MD |
| HEAD/NECK | IIT2019-20-ZUMSTEG-HPVOPC | Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer | Open/Active | Bryan Chang, MD & Zachary Zumsteg, MD |
| LUNG- NON SMALL CELL LUNG CANCER | NCI SWOG LUNGMAP | LUNGMAP: A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study) | Open/Active | Andrew Horodner, MD & Karen Reckamp, MD |
| SOLID TUMOR | "TAPUR" BY ASCO | The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, WWW.TAPUR.COM | Open/Active | Swati Sikaria, MD & Omid Hamid, MD |
| HER2(+) BREAST CANCER | IT2018-04-McArthur-neoHP | Neoadjuvant HER2-targeted Therapy and Immunotherapy | OPEN/ENROLLING | HEATHER MCARTHUR, MD (CSMC), SWATI SIKARIA, MD (TMPN) |
| HPV P16(+) Oropharyngeal Cancer | IIT2019-20-ZUMSTEG-HPVOPC | Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer | OPEN/ENROLLING | ZACHARY ZUMSTEG, MD (CSMC), VANESSA DICKEY, MD (TMPN) |
| HEAD AND NECK CANCER | NRG-HN004 | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin | OPEN/ENROLLING | ZACHARY ZUMSTEG, MD (CSMC), VANESSA DICKEY, MD (TMPN) |
| HPV (P16+) OROPHARYNGEAL CANCER | NRG-HN005 | A RANDOMIZED PHASE II/III TRIAL OF DE-INTENSIFIED RADIATION THERAPY FOR PATIENTS WITH EARLY-STAGE, P16-POSITIVE, NON-SMOKING ASSOCIATED OROPHARYNGEAL CANCER | OPEN/ENROLLING | ZACHARY ZUMSTEG, MD (CSMC), VANESSA DICKEY, MD (TMPN) |
| UNMETHYLATED GLIOBLASTOMA (GBM) | NRG-BN007 | A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA | OPEN/ENROLLING | JEREMY RUDNICK, MD (CSMC), ANDREW HORODNER, MD (TMPN) |
| LUNG- NON SMALL CELL LUNG CANCER (NSCLC) | CALITHERA CX-839-014 "KEAPSAKE" | A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) | OPEN/ENROLLING | KAREN RECKAMP, MD (CSMC), ANDREW HORODNER, MD (TMPN) |
| RENAL CELL CARCINOMA (RCC | Bristol-Myers Squibb Research and Development CA209914 | A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse "CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914" | OPEN/ENROLLING | ROBERT FIGLIN, MD (CSMC), HUGO HOOL, MD (TMPN) |
| LUNG- NON SMALL CELL LUNG CANCER (NSCLC) | SWOG LUNGMAP: S1900E | A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY | OPEN/ENROLLING | KAREN RECKAMP, MD (CSMC), ANDREW HORODNER, MD (TMPN) |
For More Information
For more information about the clinical trials at Torrance Memorial, call 310-750-3382.